Deliver the highest quality products to help doctors achieve regenerative medicine breakthroughs for their patients.
All potential EUCYT donors are screened during an examination of prenatal medical records and test results. A comprehensive medical history and a behavior-risk assessment is obtained from the donor prior to donation incorporating United States Public Health Service guidelines. We set discussions with physicians and/or donor mothers to identify circumstances that may lead to the exclusion of the donor or donated tissue.
Our infectious disease screening requirements meet, or exceed, all Food and Drug Administration requirements.
Most human tissue products are derived from cadavers and processed by third-party tissue banks. We believe the use of live, healthy donors is a superior approach to regenerative medicine.
The placental-derived allografts are recovered from live, healthy donors whom undergo a pre-screening process during pregnancy and are chosen based on our stringent donor selection criteria.
From aseptic recovery of the tissue at childbirth to timely processing of our allografts, our protocols and procedures have been developed to meet, or exceed, all applicable industry standards for the use of human cellular and tissue-based products.
Our operating entities are registered with the FDA and accredited by the AATB, AABB, and CLIA.
Our company is registered through the Food and Drug Administration (FDA) regulatory process. We take the appropriate steps to assure that EUCYT products follow FDA standards.
All EUCYT facilities and products exceed standards and are accredited. These standards cover all aspects of operation from donor selection and testing, to product processing, storage, clinical administration, and patient outcomes.